Login    Join free Add to favorites    中文
home > news > World Precision Medicine (China) Summit 2016
Industry Updates | New Products | Supplier News | Upcoming Events | business | web
World Precision Medicine (China) Summit 2016

hits:1229     Date:10/24/16

World Precision Medicine (China) Summit 2016

World Precision Medicine (China) Summit 2016
 Gaining a Clearer Perspective into Innovation Trends,
Technology Advancements and Cooperation Opportunities
December 3-4,  / Shanghai Everbright International Hotel, PRC
On January 30, 2015, US President Obama launched the Precision Medicine Initiative and precision medicine has become the spotlight of global healthcare industry. Meanwhile, Chinese President Xi Jinping appointed the NHFPC and the MOST to establish the National Precision Medicine Strategic Expert Committee. Chinese Precision Medicine Plan has been included in the 13th FYP for national major science & technology specific projects and precision medicine has become China鈥檚 national strategy. Currently, global precision medicine market values about $60 billion and the growth rate is estimated up to 15% from 2015 to 2020, which equals almost 3-4 times of the entire pharmaceutical industry. Stimulated by favorable policies and funding environment, and with the rapid technology advancements of NGS, gene editing, biochip, IVD, liquid biopsy, anti-body drugs R&D, cell immunotherapy, big data and inspiring research breakthroughs, precision medicine industry is embracing new development opportunities. 
In such context, 鈥World Precision Medicine (China) Summit 2016鈥, co-organized by Sino-American Pharmaceutical Professionals Association (SAPA), Shanghai Fenglin life Healthcare Development Co., Ltd. and Healife Group will be held on December 3-4, 2016 in Shanghai, China. Under the theme of 鈥Gaining a Clearer Perspective into Innovation Trends, Technology Advancements and Cooperation Opportunities 鈥, WPMCS2016 brings together 1,000+ senior executives from Government, academy, hospitals, big pharmas, life sciences & biotech companies,  CROs, VCPEs  to discuss the redhot topics such as China-US precision medicine market outlook and evolving regulatory landscape , big data, advanced technologies and investment opportunities, biobank & cohort study, cell immunotherapy, genetic testing &IVD, innovation & cooperation of antibody drugs, clinical therapy of tumor. Geographically, besides the delegates from Mainland China, a large number will be travelling from the United States, Europe, Israel, Japan, Korean, Singapore, Taiwan and many other countries and areas. WPMCS2016 offers an ideal balance of scientific sessions and networking opportunities, and features 100+ one-to-one meetings, 80+ eminent speakers from global precision medicine fraternity, 50+ exhibitors, 5 parallel symposiums, 2 interactive panel discussions, 1 project financing roadshow matching and our specially designed post-event US precision medicine overseas business trip.
More information about the Summit, Please visit the official event website: http://www.wpmcs.com.cn/
Any question, pls contact Ms. Karen YAU Tel: 18918108518   Email: karenyou@healife.com
Organizing Committee:
Consigned by:
Science and Technology Commission of Shanghai Municipality
Shanghai Municipal Food and Drug Administration
Shanghai Municipal Commission of Commerce
Organized by:
Sino-American Pharmaceutical Professionals Association
Shanghai Fenglin life Healthcare Development Co., Ltd.
Healife Group Co., Ltd.
Co-organized by:
Shanghai Center of Biomedicine Development
Shanghai Biopharmaceutics Industry Association
Shanghai Clinical Research Center
Shanghai Medical Instrument Trade Association
Shanghai Institute of Medical Quality
Recommend by:
European Society for Radiotherapy & Oncology
International Cancer Research Center
European Alliance for Personalized Medicine
US Chinese Anti-Cancer Association
Chinese Biopharmaceutical Association - USA
Precision Medicine Branch of China Medical Biotech Association
China Precision Medicine Technology Innovation Alliance
China Strategic Alliance of Technology Innovation for Minimally Invasive Tumor Therapy
Eminent Sponsors
WPMCS2016 Features
1,000+ senior participants from global precision medicine fraternity
500+ senior representatives from research institutions and hospitals
100+ one-to-One Meetings
80+ world-class eminent speakers
50+ exhibitors
5 parallel symposiums on: Genetic Testing &IVD, Biobank &Cohort Study, Innovation & Cooperation of Antibody Drugs, Clinical Therapy of Tumor, Cell Therapy
1 half-day project financing roadshow matching focusing on Gene Sequencing, Biochip, Liquid Biopsy, Anti-body Drugs and Cell Therapy  
Plus post-event US precision medicine business trip
Agenda Framework
Day One 3 Dec. Morning Plenary Session:
China-US Precision Medicine Market Outlook and Evolving Regulatory Landscape
Day One 3 Dec. Afternoon Plenary Session:
Big Data, Advanced Technologies and Investment Opportunities
   Day Two 4 Dec. Morning Parallel Symposiums I-III
Parallel Symposium I:
Genetic Testing &IVD
Parallel Symposium II:
Clinical Therapy of Tumor 
Parallel Symposium III:
Antibody Drugs R&D
Day Two 4 Dec. Afternoon Parallel Symposiums IV-VI
Parallel Symposium IV:
Biobank&Cohort Study
Parallel Symposium V:
Cell Therapy
Parallel Symposium VI:
Project Financing Road Show
Eminent Speakers (Inviting)
Government Officials&/Association Leaders:
China Food and Drug Administration (CFDA) Deputy Director, Wu Zhen
China National Center for Biotechnology Development Policy Coordination Director, Qiu Hongwei
China National Health and Family Planning Commission Science and Technology Director, Maxu
National Institutes of Health (NIH) Director, Francis Collins Ph.D
FDA China Office Director, Leigh Verbois Ph.D
SAPA President, Johnson& Johnson Scientific Director/Janssen Fellow, Dai Weiguo Ph.D
USCACA Chairman, Wei Zhang ph.D
ISBER Past-President, Jim Vaught ph.D
AABB Center for Cellular Therapies & Research Vice President, Naynesh Kamani
ICRC Founder, Yehia Abugabal ph.D
EAPM Executive Director, Denis Horgan
Shanghai Fenglin Life Healthcare Development Chairman, Wu Yinfei
Fudan University Public Health School Vice President& Key Lab of Health Technology Assessment Ministry of Health Director, Chen Yingyao
University Professors /Research/Medical Institutions鈥 Experts:
Fudan University Vice President, Jin Li Academician
Shanghai Cell Therapy Research Institute Director, Qian Qijun
Institute of Biophysics, Chinese Academy of Sciences Researcher, Chen Runsheng Academician
Zhongshan Hospital Fudan University President, Fan Jia
Shandong Cancer Hospital President Yu Jinming
Tianjin Cancer Hospital President& Tumor Precision Medicine Big Data Center Director, Wangping
The Affiliated Hospital of Nanjing University Medical School Vice President/ Tumor Center Director, Liu Baorui
Ruijin Hospital Vice President, Ning Guang Academician
US National Cancer Institute Director, Dimiter S Dimitrov
Mayo Clinic Technology Assessment Group Center for Individualized Medicine Chairman, David Smith
Wake Forest University Baptist Comprehensive Cancer Center Director, Boris Pasche
University of Texas MD Anderson Cancer Center Tenured Associate Professor, Liang Han
University of Colorado Division of Medical Oncology Distinguished Professor, Paul Bunn
Cancer Research UK Precision Medicine Head, Rowena Sharpe
Sweden Karolinska Institute Medical School Professor, Roman A. Zubarev
German university of Brunswick Professor, Stefan Dbel
National Taiwan University Professor, Eric Y. Chuang
Seoul National University Hospital Professor& Korea National Academy of Sciences Director, Yung-Jue Bang
Ministry of Health, Xiangya Hospital Central South University, Key Laboratory of Cancer Proteomics Professor, Zhan Xianquan
Shanghai Center for Drug Discovery & Development Director, Shao Liming
Tongji University School of Medicine Dean& Professor, Xu Guotong
Shanghai Institutes for Biological Sciences Director, Li Yixue
Jiangsu Province Hospital Vice President, Zhao Jun
Peking University Health Science Center School of Public Health Professor, Li Liming
Fudan University Biomedical Sciences Institutes Professor, Liu Lei
Xiamen University TMRC &CTCTCT Professor& Executive Director, Zeng Jimeng
Hebei University of Science and Technology Associate Professor, Han Chunyu
Global Precision Medicine enterprises/VCPE Senior Executives
BGI Chairman, Wang Jian Academician
Illumina Greater China General Manager, Zhao Ruilin
Eli Lilly and Company China Drug Development Senior Vice President, Kerry Blanchard
Johnson& Johnson Asia-Pacfic Innovation Center Senior Director, Xia Mingde
IMB Watson Health China Head & Innovation Division CTO, Wu Yiduo
Alibaba Cloud Computing President & Alibaba Group Vice President, Hu Xiaoming
Intel Health and Life Science General Mangager Asia- Pacific Region, Carl Li
Qiagen General Manager, Nick Zhang
CapitalBio Corporation Associate Researcher, Guo Hongyan
Amgen Vice President of Global R&D, Zhang Mingqiang
Genentech Executive Vice President, Global Development and Chief Medical Officer, Sandra Horning
LabCorp Chairman & CEO, David King
Roche Diagnostics Principle Scientist Jan Kuentzer
Merck Vice President, Head of Translational Medicine, Robert Plenge
Regeneron Phamarceuticals, Regeneron Laboratories &Chief Science Officer, President, George Yancopoulos
GSK Oncology SVP, TA Head Oncology R&D, Chris Carpenter
Macrogen, NGS Division, General Manager, Bon-Chao Kim
Jiangsu Hengrui Medicine Co, .Ltd, Vice President of Global R&D, Zhang Lianshan
Seattle Genetics CMO & EVP, Research and Development, Jonathan Drachman
CP Guojian Pharm President, Wang Junlin
Genor BioPharma CEO, Zhou Xinhua
CloudHealth Genomics Partner& President, Jin Gang
Roche Diagnostics China CEO, Huang Boxing
Burning Rock Dx Founder, Han Yusheng
Dian Diagnostics Chairman, Chen Haibin
Berry Genomics Chairman, Gao Yang
Haplox Founder & CEO, Xu Mingyan
BVCF Fund, Founding Partner, Yang Zhi
Sequoia Capital Partner, Chen Penghui
GTJA Investment Group Executive Partner, Wang Haijiao
V-Stone Investment Partner, Yu Tiecheng
Touwho CEO, Zhao Yanyu
Firestone Founder & CEO, Yang Hongfei
Related News>> more

Copyright(C) 2006-2018 Bio-Equip    E-mail:web@bio-equip.cn   娌狪CP澶06040519鍙